FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

Patients were in their early 50s on average, and some 80% were women. Nearly all were white (most participants were from ...

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at ...

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical app ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

Nurix is eligible for an additional $420 million in development, regulatory and commercial milestones associated with the ...

Boehringer Ingelheim and Cue Biopharma have entered a strategic research partnership and licence agreement to develop and commercialise the latter’s CUE-501 product candidate for autoimmune conditions ...

A desi dengue vaccine is undergoing the third phase of clinical trials in India, a top Indian Council of Medical Research ...

Boehringer Ingelheim and Cue Biopharma Inc. have joined forces to develop and commercialize Cue Biopharma’s CUE-501 product candidate.

Cue Biopharma (CUE) stock in focus as the company collaborates with Boehringer Ingelheim to develop CUE-501, for autoimmune ...

The global antibody discovery market size is anticipated to reach approximately USD 22,570 million by 2034, up from USD 9,570 ...